Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Xudong Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5587-4448; OpenAlex author ID A5101951895, A5123642437. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
37
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 4 papers · 2022: none · 2023: 4 papers · 2024: 1 paper · 2025: 4 papers · 2026: 1 paper

Papers 16

  1. NSUN6 deficiency drives immune suppression in pancreatic cancer via the KDM5A-CCL2-macrophage axis. Co-author DOI 10.1136/gutjnl-2025-336541↗
  2. Extracellular vesicles from obese visceral adipose promote pancreatic cancer development and resistance to immune checkpoint blockade therapy. Co-author DOI 10.1016/j.cmet.2025.10.015↗
  3. CSTF2-impeded innate αβ T cell infiltration and activation exacerbate immune evasion of pancreatic cancer. Co-author DOI 10.1038/s41418-025-01464-0↗
  4. Psychological stress-induced ALKBH5 deficiency promotes tumour innervation and pancreatic cancer via extracellular vesicle transfer of RNA. Co-author DOI 10.1038/s41556-025-01667-0↗
  5. Targeting MXD1 sensitises pancreatic cancer to trametinib. Last author DOI 10.1136/gutjnl-2024-333408↗
  6. KHSRP Stabilizes m6A-Modified Transcripts to Activate FAK Signaling and Promote Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1158/0008-5472.can-24-0927↗
  7. LncRNA BCAN-AS1 stabilizes c-Myc via N6-methyladenosine-mediated binding with SNIP1 to promote pancreatic cancer. Co-author DOI 10.1038/s41418-023-01225-x↗
  8. CSTF2 mediated mRNA N6-methyladenosine modification drives pancreatic ductal adenocarcinoma m6A subtypes. Co-author DOI 10.1038/s41467-023-41861-y↗
  9. Super-enhancer RNA m6A promotes local chromatin accessibility and oncogene transcription in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41588-023-01568-8↗
  10. N 6-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-22-3346↗
  11. LINC00842 inactivates transcription co-regulator PGC-1α to promote pancreatic cancer malignancy through metabolic remodelling. Co-author DOI 10.1038/s41467-021-23904-4↗
  12. N6 -methyladenosine-Mediated Upregulation of WTAPP1 Promotes WTAP Translation and Wnt Signaling to Facilitate Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-21-0494↗
  13. Inflammatory cytokine-regulated tRNA-derived fragment tRF-21 suppresses pancreatic ductal adenocarcinoma progression. First author DOI 10.1172/jci148130↗
  14. Genome-wide identification and characterization of circular RNA m6A modification in pancreatic cancer. Co-author DOI 10.1186/s13073-021-01002-w↗
  15. Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine. Co-author DOI 10.7150/thno.23978↗
  16. Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. First author DOI 10.1038/ng.3568↗

Closest collaborators

The 25 strongest of 37 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jialiang Zhang · 14 shared papers, 2021–2026 · strength 2.10
  2. Lingxing Zeng · 13 shared papers, 2021–2026 · strength 2.00
  3. Jian Zheng · 15 shared papers, 2016–2025 · strength 1.99
  4. Dongxin Lin · 15 shared papers, 2016–2025 · strength 1.99
  5. Shaoping Zhang · 11 shared papers, 2021–2025 · strength 1.58
  6. Ziming Chen · 7 shared papers, 2023–2026 · strength 1.28
  7. Zilan Xu · 7 shared papers, 2023–2026 · strength 1.28
  8. Chunling Xue · 7 shared papers, 2023–2026 · strength 1.28
  9. Jiachun Su · 9 shared papers, 2021–2026 · strength 1.19
  10. Rufu Chen · 8 shared papers, 2021–2024 · strength 0.98
  11. Quanbo Zhou · 6 shared papers, 2023–2025 · strength 0.91
  12. Xiaowei He · 5 shared papers, 2023–2025 · strength 0.86
  13. Yanfen Zheng · 6 shared papers, 2021–2023 · strength 0.68
  14. Rui Li · 5 shared papers, 2021–2024 · strength 0.68
  15. Ying Ye · 5 shared papers, 2021–2023 · strength 0.58
  16. Junge Deng · 5 shared papers, 2021–2023 · strength 0.54
  17. Zhixiang Zuo · 4 shared papers, 2021–2023 · strength 0.48
  18. Guandi Wu · 4 shared papers, 2021–2023 · strength 0.44
  19. Lusheng Wei · 4 shared papers, 2021 · strength 0.40
  20. Xiaoyu Wu · 2 shared papers, 2025 · strength 0.38
  21. Xu Che · 4 shared papers, 2016–2021 · strength 0.31
  22. Chen Hsuan Wu · 4 shared papers, 2016–2021 · strength 0.31
  23. Ling Pan · 3 shared papers, 2021 · strength 0.29
  24. Qi Zhou · 1 shared paper, 2026 · strength 0.23
  25. Chengfeng Wang · 3 shared papers, 2016–2021 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.